TOKYO-METROPOLITAN
6.7.2021 16:06:06 CEST | Business Wire | Press release
With the Olympic Games just around the corner, Tokyo Governor Koike Yuriko sent a video message to the world's media inviting them to the Tokyo Media Center (TMC) provided by the Tokyo Metropolitan Government. TMC offers services not only for members of the press coming to Tokyo but also those working from their home countries, a great opportunity to cover the Games and the City online no matter how far away. Registration is required for full use of member services. Do not miss the opportunity to receive regular full online updates about what’s happening in Tokyo during the Games!
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210706005509/en/
Find the video invitation form Koike Yuriko, the Governor of Tokyo at https://tokyo.mediacenter.jp/about/
Register Now!
| 1) | Access TMC’s registration page at https://tokyo.mediacenter.jp/?modal=register |
|
| 2) | Submit your name and email for Account Registration. |
|
| 3) | Register your ID and proof of employment with the Accreditation Application at https://tokyo.mediacenter.jp/login/ |
Benefits of TMC Online Service
1) |
TMC Web will be your home for various information during the Games, including photos, videos, data regarding Tokyo and more. |
|
2) |
TMC Newsletters will update you twice a day with what’s happening in Tokyo during the Games. |
|
3) |
TMC Briefings will live-stream daily briefings from the Tokyo Metropolitan Government. You can cast questions to the officials. They are scheduled from 12:30 pm to 1:00 pm, Japan Standard Time (JST), from July 23 to August 8 and from August 24 to September 5, 2021. |
|
4) |
TMC Talks will video-stream daily live presentations and recorded messages by Governor Koike and/or global leaders from various fields such as sports, culture and urban development. The main theme will be the future of Tokyo. You can cast questions to speakers via online tools. More details about TMC Talks will be announced soon. They are scheduled from 2:00 pm to 2:40 pm, JST, from July 21 to August 8 and from August 23 to September 5, 2021. |
|
5) |
TMC Online Concierge will answer your questions and provide consultations about Tokyo-related coverage and photography. It will be available between 8:00 am and 10:00 pm, JST, from July 21 to August 8 and from August 23 to September 5, 2021. |
We are looking forward to serving you soon!
About the Tokyo Media Center (TMC)
The Tokyo Media Center (TMC) has been set up by the Tokyo Metropolitan Government to serve as a media coverage base for domestic and international media during the Olympic and Paralympic Games Tokyo 2020. TMC provides information related to the host city Tokyo as well as the Tokyo 2020 Games. It is totally separate from the Main Press Centre (MPC) and International Broadcast Centre (IBC), which are operated by the Tokyo 2020 Organising Committee.
Website
URL: https://tokyo.mediacenter.jp/
Facilities
Date and Time of Opening: |
|
Wednesday, July 21, 2021 to Monday, August 9, 8:00 am to 10:00 pm, JST |
|
Monday, August 23, 2021 to Sunday, September 5, 8:00 am to 10:00 pm, JST |
|
* A pre-opening is scheduled on Monday, July 19 and Tuesday, July 20. The details will be announced separately. |
|
Access: |
Tokyo Sports Square, 2nd and 3rd Floor (address: Marunouchi 3-8-3, Chiyoda-ku, Tokyo) |
1 minute walk from JR Yurakucho Station and Tokyo Metro Yurakucho Station |
|
Services: |
Workspace and lounge |
Approximately 120 seats available to create a work environment for journalists. |
|
A drink corner offering refreshments will also be provided. |
|
Information Desk |
|
Staff will respond to inquiries regarding facilities usage. Upon first entrance, guests will receive a media kit which includes complimentary Tokyo-related giveaways. |
|
Japan Showcase |
|
The Japan National Tourism Organization (JNTO) will have booths to promote Japan’s various regions and traditional culture. |
|
Japanese Liquors Booth |
|
The National Tax Agency (NTA) will have a booth to introduce Japanese liquors. |
|
Internet Connection |
|
Wi-fi available for use by registered members. |
|
* Detailed information such as COVID-19 countermeasures and how to enter the facilities will be periodically updated on the TMC website and TMC Briefings. |
|
TOKYO UPDATES
Tokyo Metropolitan Government (TMG) launched a new media platform to show the world the ever-changing face of Tokyo now and the future in May 2021. This platform features content such as articles which focus on the attractions of Tokyo and the people who live, study, and work in the city. Please be sure to check it out.
URL: https://www.tokyoupdates.metro.tokyo.lg.jp/en/
View source version on businesswire.com: https://www.businesswire.com/news/home/20210706005509/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom